Next-generation Prostate Cancer Biobanking

Esgueva, Raquel; Park, Kyung; Kim, Robert; Kitabayashi, Naoki; Barbieri, Christopher E.; Dorsey, Philip; Abraham, Cyril; Banerjee, Samprit; Leung, Robert; Tewari, Ashutosh; Terry, Stéphane; Shevchuk, Maria M.; Rickman, David S.; Rubin, Mark A.

doi:10.1097/pdm.0b013e31823b6da6

Cited by 26 publications

(11 citation statements)

References 28 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These are placed in a dry ice and methylbutane bath and stored at −80°C. 1,6 In addition, fresh tissue is immediately transported to the laboratory for xenograft and tumor organoid development. 2 See Data Supplement for sample autopsy findings.…”

Section: Methodsmentioning

confidence: 99%

“…Institutional rapid autopsy programs have been well described 1,3–12 and have previously led to significant advances in cancer research in the areas of prostate, 1,3,4,6,7,11 pancreas, 10 breast, 8 and pediatric brain tumors. 5,9,12 This program builds on prior autopsy programs by enrolling patients of all ages and cancer types, capturing samples throughout a patient’s disease course, and leveraging multiple parallel platforms to generate high-throughput sequencing data and robust preclinical tumor models.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models

Pisapia

Salvatore

Pauli

et al. 2017

JCO Precision Oncology

Self Cite

View full text Add to dashboard Cite

Purpose Patients with cancer who graciously consent for autopsy represent an invaluable resource for the study of cancer biology. To advance the study of tumor evolution, metastases, and resistance to treatment, we developed a next-generation rapid autopsy program integrated within a broader precision medicine clinical trial that interrogates pre- and postmortem tissue samples for patients of all ages and cancer types. Materials and Methods One hundred twenty-three (22%) of 554 patients who consented to the clinical trial also consented for rapid autopsy. This report comprises the first 15 autopsies, including patients with metastatic carcinoma (n = 10), melanoma (n = 1), and glioma (n = 4). Whole-exome sequencing (WES) was performed on frozen autopsy tumor samples from multiple anatomic sites and on non-neoplastic tissue. RNA sequencing (RNA-Seq) was performed on a subset of frozen samples. Tissue was also used for the development of preclinical models, including tumor organoids and patient-derived xenografts. Results Three hundred forty-six frozen samples were procured in total. WES was performed on 113 samples and RNA-Seq on 72 samples. Successful cell strain, tumor organoid, and/or patient-derived xenograft development was achieved in four samples, including an inoperable pediatric glioma. WES data were used to assess clonal evolution and molecular heterogeneity of tumors in individual patients. Mutational profiles of primary tumors and metastases yielded candidate mediators of metastatic spread and organotropism including CUL9 and PIGM in metastatic ependymoma and ANKRD52 in metastatic melanoma to the lung. RNA-Seq data identified novel gene fusion candidates. Conclusion A next-generation sequencing–based autopsy program in conjunction with a pre-mortem precision medicine pipeline for diverse tumors affords a valuable window into clonal evolution, metastasis, and alterations underlying treatment. Moreover, such an autopsy program yields robust preclinical models of disease.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models

Pisapia

Salvatore

Pauli

et al. 2017

JCO Precision Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hospital-based or single institutional biobanks which may include smaller collections of samples or samples from multiple studies with common storage and governance, may increase their power by joining together to form networks or consortia to execute research studies 10 . There are other biobanks focusing on amassing large populations of samples from persons with specific conditions such as AIDS 11 , Diabetes 12 , Prostate cancer 13 , or Psoriasis 14 . Rare disease biobanks and biobanks created through consumer websites are increasingly becoming available, particularly as disease advocacy organizations and genetic testing companies recognize the ability of motivated organizations and individuals to accelerate translational research 15,16 .…”

Section: Introductionmentioning

confidence: 99%

Biobanking: The Melding of Research with Clinical Care

Smith

Aufox

2013

Curr Genet Med Rep

View full text Add to dashboard Cite

The number of biobanks around the world has increased dramatically, owing in part, to the need for researchers to have access to large numbers of samples for genomic research. Policies for enrolling participants, returning research results and obtaining samples and data can have a far reaching impact on the type of research that can be performed with each biobank. Research using biobank samples includes studies of the impact of environmental and other risk exposures on health, understanding genetic risks for common disease, identification of biomarkers in disease progression and prognosis, and implementation of personalized medicine projects. This research has been instrumental in the progress of genetic and genomic research and translational medicine. This article will highlight some of the controversies and recent research associated with biobanking over the past year.

show abstract

“…Our previous Annual Report documented 5 goals for the 3 rd year of operation: (1) Our primary goal is to increase usage, (2) In concert with this goal we intend to increase accrual of high demand samples, i.e. metastatic and high risk disease tissues, derivatives, and specimens from African Americans, (3) A major goal is to conduct the Workshop, (4) Conduct biospecimen science studies to evaluate how variation in fixation parameters and ischemia affect a range of commonly used biomarkers, using our newly constructed Fixation and Ischemia TMAs, (5) Write a manuscript describing the development of the PCBN and lessons learned.…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer Pathology Resource Network

Trock¹

2013

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

show abstract

Next-generation Prostate Cancer Biobanking

Cited by 26 publications

References 28 publications

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models

Biobanking: The Melding of Research with Clinical Care

Prostate Cancer Pathology Resource Network

Contact Info

Product

Resources

About